Comparison of clinical and immunological profiles in coronavirus disease 2019 and influenza patients: a case control study

doi:10.5847/wjem.j.1920-8642.2022.042

World Journal of Emergency Medicine ›› 2022, Vol. 13 ›› Issue (4): 309-312.doi: 10.5847/wjem.j.1920-8642.2022.042

• Research Letters • Previous Articles Next Articles

Comparison of clinical and immunological profiles in coronavirus disease 2019 and influenza patients: a case control study

Zhao-di Wang¹^,², Cong-ying Song¹^,², Da-gan Yang³, Yun-mei Yang¹^,², Yuan-qiang Lu¹^,²()

¹Department of Geriatric and Emergency, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, China
²Key Laboratory for Diagnosis and Treatment of Aging and Physic-chemical Injury Diseases of Zhejiang Province, Hangzhou 310003, China
³Department of Laboratory Medicine, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310003, China

Received:2021-10-20 Accepted:2022-01-10 Online:2022-06-23 Published:2022-07-01
Contact: Yuan-qiang Lu E-mail:luyuanqiang@zju.edu.cn

1. Supplementary Table1 The independent factors of COVID-19 or influenza.docx(17KB)

Abstract

Zhao-di Wang, Cong-ying Song, Da-gan Yang, Yun-mei Yang, Yuan-qiang Lu. Comparison of clinical and immunological profiles in coronavirus disease 2019 and influenza patients: a case control study[J]. World Journal of Emergency Medicine, 2022, 13(4): 309-312.

Figures/Tables 2

Table 1.

Comparisons of characteristics between COVID-19 and influenza patients

Demographic and clinical characteristics	COVID-19 patients (n=79)	Influenza patients (n=75)	P-value
Age, years	54 (45-63)	59 (48-70)	0.082
Sex			0.670
Male	49 (62.0)	44 (58.7)
Female	30 (38.0)	31 (41.3)
Symptoms
Fever	74 (93.7)	71 (94.7)	0.792
Cough	47 (59.5)	65 (86.7)	<0.001
Expectoration	23 (29.1)	52 (69.3)	<0.001
Headache	8 (10.1)	24 (32.0)	0.001
Myalgia or fatigue	23 (29.1)	25 (33.0)	0.572
Chill	6 (7.6)	29 (38.7)	<0.001
Pharyngalgia	4 (5.1)	7 (9.3)	0.304
Dyspnea	20 (25.3)	27 (36.0)	0.150
Nausea or vomiting	3 (3.8)	4 (5.3)	0.674
Basic vital signs
T_max,℃	38.2 (37.5-38.9)	38.9 (37.7-39.5)	0.014
Temperature at hospital admission, ℃	37.0 (36.6-37.5)	37.5 (37.0-38.0)	<0.001
Respiratory rate, breaths/min	18.0 (18.0-20.0)	20.0 (18.0-20.0)	0.014
Heart rate, beats/min	87.0 (78.0-95.0)	87.0 (78.0-100.0)	0.519
Mean arterial pressure, mmHg	100.0 (87.0-108.3)	96.0 (91.7-104.3)	0.831
Coexisting disorders
Hypertension	29 (36.7)	29 (38.7)	0.802
Diabetes	12 (15.2)	13 (17.3)	0.718
Cardiovascular disease	5 (6.3)	11 (14.7)	0.090
Chronic obstructive pulmonary disease	4 (5.1)	6 (8.0)	0.460
Chronic liver disease	9 (11.4)	10 (13.3)	0.714
Chronic kidney disease	3 (3.8)	6 (8.0)	0.266
CPIS	2.0 (1.0-3.0)	2.0 (1.0-4.0)	0.310
CT severity score	10.0 (6.0-16.0)	9.0 (6.0-18.0)	0.892
Days from illness onset to hospital admission, d	5.0 (2.0-7.0)	6.0 (3.0-7.0)	0.052
Receiving treatment before admission	40 (50.6)	53 (70.0)	0.011
Antibiotics	18 (22.8)	45 (60.0)	<0.001
Oseltamivir	10 (12.7)	26 (34.7)	0.001
Lopinaviritonavir	23 (29.1)	0 (0.0)	<0.001
Hormones	22 (27.8)	18 (24.0)	0.586
Length of hospital stay, d	17 (14-24)	8 (5-14)	<0.001
Laboratory results
White blood cell count, ×10⁹/L	5.7 (3.9-8.7)	6.0 (4.1-9.5)	0.486
Neutrophil count, ×10⁹/L	4.1 (2.5-7.2)	4.2 (2.5-7.2)	0.915
Lymphocyte count, ×10⁹/L	0.8 (0.5-1.2)	0.9 (0.6-1.4)	0.084
NLR	5.5 (2.3-14.3)	4.4 (2.4-11.7)	0.345
Monocyte count, ×10⁹/L	0.3 (0.2-0.5)	0.5 (0.3-0.7)	0.004
Platelet count, ×10⁹/L	191.0 (145.0-234.0)	165.0 (124.0-234.0)	0.102
Hemoglobin, g/L	141.0 (127.0-150.0)	121.0 (107.0-140.0)	<0.001
Red blood cell distribution width, %	12.2 (11.9-12.7)	12.8 (12.2-14.0)	<0.001
Erythrocyte sedimentation rate, mm/h	30.0 (14.0-60.0)	40.0 (19.0-58.0)	0.402
C-reactive protein, mg/L	24.3 (9.4-51.2)	32.3 (13.7-82.1)	0.068
Procalcitonin, ng/mL	0.06 (0.04-0.09)	0.15 (0.07-0.44)	<0.001
Lactose dehydrogenase, U/L	246.0 (206.0-337.0)	244.0 (193.0-375.4)	0.800
Hydroxybutyrate dehydrogenase, U/L	207.0 (172.0-276.0)	209.0 (168.0-322.6)	0.641

Table 1.

Figure 1.

References 9

1	Patel PM. Cardiovascular testing during COVID-19: chaos of an orchestra rehearsal but signs of a harmonious symphony. JACC: Asia. 2021; 1 (2):200-2. doi: 10.1016/j.jacasi.2021.08.001
2	Lu YQ. A woman with fever and cough: coronavirus disease 2019. Intern Emerg Med. 2020; 15(8):1553-4. doi: 10.1007/s11739-020-02321-3
3	Tang X, Du RH, Wang R, Cao TZ, Guan LL, Yang CQ, et al. Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1. Chest. 2020; 158(1):195-205. doi: 10.1016/j.chest.2020.03.032
4	Song CY, Yang DG, Lu YQ. A COVID-19 patient with seven consecutive false-negative rRT-PCR results from sputum specimens. Intern Emerg Med. 2020; 15(5):871-4. doi: 10.1007/s11739-020-02423-y
5	Qin C, Zhou LQ, Hu ZW, Zhang SQ, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15):762-8. doi: 10.1093/cid/ciaa248
6	Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020; 46(6):1105-8. doi: 10.1007/s00134-020-06059-6 pmid: 32347323
7	Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: friend or foe? Life Sci. 2020; 256:117900. doi: 10.1016/j.lfs.2020.117900
8	Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014; 2(8):611-20. doi: 10.1016/S2213-2600(14)70097-9
9	Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020; 98(1):219-27. doi: 10.1016/j.kint.2020.04.003

Comparison of clinical and immunological profiles in coronavirus disease 2019 and influenza patients: a case control study

RichHTML

PDF (PC)

Supplement

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 9

Related Articles 0

Recommended Articles

Comments